Molecular Pathology

Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...

Thought this was worth sharing from MIT Technology Review. After attending ASCO last week what I thought might happen a year or two again actually has. Pathologists no longer have to worry about stepping out from behind the paraffin curtain...

VisionGate, Inc. recently announced the appointment of Dr. David Wilbur as Medical Director of its Phoenix-based CLIA laboratory, VisionGate Biosignatures Laboratory (VBL). A world-renowned pathologist, Dr. Wilbur comes to VisionGate from...

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...

Fierce Healthcare (5/2, Sweeney) reports on a Medscape survey finding that among oncologists, about 70% “believe genetic testing is very important or extremely important to oncology, but 55% also say genomic testing is overpromoted.” One...

Dr. Heritage is widely recognized for his work in the development of informatics systems for drug and performance chemical discovery, translational and personalized medicine, and pharmaceutical product development. San Francisco, CA, February...